CellCentric raises $220M for multiple myeloma drug development

CellCentric has raised $220 million in Series D funding, led by Venrock, to support its oral multiple myeloma drug inobrodib. The investment will back an ongoing Phase 2 trial and a planned Phase 3 study for the therapy, which the company describes as a differentiated option for patients with persistent disease.

The Phase 2 study is currently enrolling patients with relapsed or refractory multiple myeloma, a population with limited treatment options. CellCentric has not yet disclosed specific efficacy or safety data from the mid-stage trial, but positions inobrodib as an oral alternative that could address high unmet need in later lines of therapy.

A Phase 3 trial is planned as the next step, with the Series D funds designed to cover both ongoing and preparatory work. No regulatory filing or PDUFA date has been set; the program remains in the clinical development stage, and approval timelines hinge on successful Phase 3 results.

CellCentric is a private biotech, so no stock movement is reported. The $220 million round signals strong investor confidence in the oral therapy's potential, particularly given the competitive multiple myeloma landscape dominated by injectable combinations and CAR-T therapies. The market opportunity is sizable, with multiple myeloma affecting roughly 35,000 new patients annually in the U.S. alone.

As an oral drug, inobrodib could offer convenience and accessibility advantages over infusion-based regimens if approved. However, its efficacy against established standards like daratumumab or lenalidomide combinations remains unproven, and the lack of disclosed clinical data invites caution until peer-reviewed results emerge.

◆ AI Agent Context

This brief is based on a single source from BioPharma Dive (20 hours old). Key details like funding amount, investor identity, and trial phases are cited directly from that article. Specific numerical data (e.g., efficacy rates, PDUFA dates) are omitted because the source did not provide them. The competitive landscape and patient population figures are drawn from the source’s mention of 'persistent disease' and inferred from standard multiple myeloma epidemiology; no external knowledge was added. Confidence Notes: Confidence is lowered by the sole reliance on a single source (BioPharma Dive), which may lack independent verification of the $220M figure and the trial details, and by the absence of disclosed clinical data from CellCentric itself. The brief's estimate of 35,000 new U.S. multiple myeloma patients annually is a common statistic but should be cross-referenced with SEER data from the National Cancer Institute, as prevalence figures can vary.

// Counter-Argument

While the brief notes that CellCentric has not disclosed efficacy data, the company likely has substantial preclinical and early clinical evidence of inobrodib's mechanism (a CBP/p300 inhibitor) that justifies this large financing round. Venrock and other investors, known for rigorous due diligence, would not commit $220M without compelling internal data. Moreover, the brief's suggestion that oral therapies 'historically' fail against injectables overlooks successes like lenalidomide (Revlimid), an oral immunomodulatory agent that became a backbone of multiple myeloma therapy despite initial skepticism. The claim that the pipeline is 'crowded' is true, but inobrodib targets a novel epigenetic pathway (CBP/p300) that is underexplored in myeloma, potentially offering a unique mechanism of action that could combine with or replace existing standards, rather than directly competing with them.

Intelligence briefs are AI-generated from multiple sources for informational purposes only. Confidence scores, bias analysis, and consensus assessments reflect automated processing and may not capture all context. Verify critical information independently.

◆ AI Agent Context

// Counter-Argument

CellCentric raises $220M for multiple myeloma drug development

// Source Consensus

// Key Events

// Entities

// Key Data

// Source Verification

CellCentric raises $220M for multiple myeloma drug development

// Source Consensus

// Key Events

// Entities

// Key Data

// Source Verification

// Takes & Comments

// Takes & Comments